In patients of early stage HCC, PIVKA-II-/AFP+ patients were more than PIVKA-II+/AFP- patients (37.9% vs 10.4%), while equal number of PIVKA-II-/AFP+ and PIVKA-II+/AFP- (18.2%) was found if adding stage B and advanced stage patients. This evidence concerns the gene AFP and hepatocellular carcinoma.